Summit Healthcare Acquisition Corp.
SMIHU
NASDAQ Capital Market12.15
USD
+0.72
- -
CIK
0001839185
CUSIP
G8566R128
Return %
Stock
S&P500
1Y
23.98
18.21
3Y
21.50
64.38
5Y
21.50
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Bo Tan
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1 Lyndhurst Tower Central Hong Kong
- CIK
- 0001839185
- Similar Companies
- Business
- Summit Healthcare Acquisition Corp. (SMIHU) operates as a blank-check company focused on effecting mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations, primarily targeting businesses in the healthcare sector; it conducts no significant independent operations. Incorporated in 2020 and headquartered in Central, Hong Kong, the company previously traded on Nasdaq under SMIHU for its units comprising one Class A ordinary share and one-half of one redeemable warrant. In March 2023, Summit Healthcare Acquisition Corp. completed a reverse merger transaction with YS Biopharma Co., Ltd., a global biopharmaceutical firm specializing in innovative vaccines and therapeutic biologics using its proprietary PIKA immunomodulating technology platform; post-merger, YS Biopharma continues operations with commercial products including the YSJATM rabies vaccine, administered to approximately 16 million patients across China via coverage of 27 province-level and 1,700 county-level CDCs, alongside pipeline candidates such as PIKA rabies vaccine, PIKA YS-HBV-001 and PIKA YS-HBV-002 for hepatitis B, YS-ON-001 and YS-ON-002 immuno-oncology therapies for solid tumors, PIKA influenza vaccine, and recombinant COVID-19 vaccine YS-SC2-010.